|1.||Holst, Jens J: 4 articles (01/2015 - 04/2008)|
|2.||Delzenne, Nathalie M: 4 articles (01/2012 - 08/2006)|
|3.||Cani, Patrice D: 4 articles (01/2012 - 08/2006)|
|4.||Murata, Yoshiharu: 3 articles (01/2015 - 01/2013)|
|5.||Hayashi, Yoshitaka: 3 articles (01/2015 - 01/2013)|
|6.||Vrang, Niels: 3 articles (01/2013 - 04/2002)|
|7.||Jin, Tianru: 3 articles (09/2012 - 06/2005)|
|8.||Ney, Denise M: 3 articles (09/2012 - 04/2008)|
|9.||Holst, J J: 3 articles (10/2011 - 06/2001)|
|10.||Drucker, Daniel J: 3 articles (11/2005 - 07/2002)|
07/23/1996 - "We demonstrate that nude mice bearing subcutaneous proglucagon-producing tumors exhibit marked proliferation of the small intestinal epithelium. "
11/01/1994 - "Examination of proglucagon posttranslational processing in the tumors demonstrated that proglucagon was processed differently in each tumor to yield a unique profile of PGDPs. "
11/01/1994 - "Plasma levels of the PGDPs were elevated in all tumor-bearing mice (8- to 22-fold greater than controls, P < 0.001), and this was associated with marked inhibition of mouse pancreatic proglucagon gene expression. "
11/01/1994 - "Inhibition of pancreatic proglucagon gene expression in mice bearing subcutaneous endocrine tumors."
11/01/1994 - "GLUTag tumors may be passaged in vivo and in vitro and have been used to generate stable cell lines that express the proglucagon gene at high levels. "
|2.||Short Bowel Syndrome
07/01/1998 - "In summary, SCFAs led to rapid changes in ileal proglucagon and glucose transporter expression in rats receiving TPN and provide insights into therapeutic management of individuals with short bowel syndrome or intestinal malabsorption syndromes."
09/01/2012 - "Glucagon-like peptide-2 (GLP-2) is a nutrient-dependent, proglucagon-derived gut hormone that shows promise for the treatment of short bowel syndrome (SBS). "
12/01/2010 - "Glucagon-like peptide-2 (GLP-2) is a nutrient-dependent, proglucagon-derived hormone that is a proposed treatment for human short bowel syndrome (SBS). "
01/01/2015 - "Mucosal inflammation induced the overexpression of GPR40, GPR120, and several inflammatory cytokines, with correlations between ileal concentrations of tumor necrosis factor (TNF)-α and GPR expression levels; however, inflammation did not induce the expression of proglucagon, a precursor of GLP-2 in CD patients. "
11/01/2011 - "In addition, prebiotics improved glucose tolerance, increased L-cell number and associated parameters (intestinal proglucagon mRNA expression and plasma glucagon-like peptide-1 levels), and reduced fat-mass development, oxidative stress, and low-grade inflammation. "
07/01/2005 - "This report describes a study using the rat insulinoma cell line RIN-1056A, which abundantly expresses both insulin and proglucagon (glu), and relatively high amounts of endogenous Cdx-2. "
04/01/2005 - "To investigate whether mouse insulinoma (MIN6) cells transfected with the glucagon like peptide-1 (GLP-1) fragment of the proglucagon gene (RIP/GLP-1 MIN6 cells) are resistant to the toxicity derived from the administration of ISD. "
12/26/1997 - "To understand better the biosynthetic pathway of tGLP-1, proglucagon processing was studied in the mouse pituitary cell line AtT-20, a cell line that mimics the intestinal pathway of proglucagon processing and in the rat insulinoma cell line INS-1. "
05/01/1979 - "For example, insulinoma and glucagonoma can be diagnosed more readily by demonstration of proinsulin and proglucagon-like components, respectively, in the blood. "
09/01/2002 - "We transfected mouse insulinoma cells with a DNA fragment of the human proglucagon gene containing the nucleotide sequence encoding for human GLP-1 but lacking the coding region for glucagon. "
|5.||Type 2 Diabetes Mellitus (MODY)
01/01/2000 - "Lack of germline mutations in the preproglucagon gene region coding for glucagon-like peptide 1 in Type 2 diabetic (NIDDM) patients."
02/01/1991 - "After oral glucose the insulin concentrations in plasma were lower and the concentrations of all proglucagon products were higher in the NIDDM group compared to the control group. "
02/01/1991 - "We investigated the major products of proglucagon (PG) processing in plasma in the fasting state, after intravenous arginine and after an oral glucose load in noninsulin-dependent diabetics (NIDDM) and in weight matched controls using specific radioimmunoassays and analytical gel filtration. "
12/01/2014 - "The aim of this study was to investigate the messenger RNA (mRNA) gene expression of proglucagon, glucose-dependent insulinotropic peptide (GIP), prohormone convertase 1/3 (PC1/3), and dipeptidyl peptidase-IV (DPP-IV) in jejunum cells of the morbidly obese (OB) non type 2 diabetes mellitus (NDM2) and type 2 diabetes mellitus (T2DM), to determine the molecular basis of incretin secretion after bariatric surgery. "
|2.||Messenger RNA (mRNA)
|3.||Glucagon-Like Peptide 1 (GLP 1)
|2.||Transplantation (Transplant Recipients)
|3.||Drug Therapy (Chemotherapy)